Decompensated Cirrhosis of Liver
8
4
5
1
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 25/100
0.0%
0 terminated out of 8 trials
100.0%
+13.5% vs benchmark
0%
0 trials in Phase 3/4
100%
1 of 1 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (8)
Using Telemedicine to Assist in the Clinical Care of Patients With Decompensated Cirrhosis
Statin and Beta Blocker Use in Patients With Decompensated Cirrhosis
Introducing Palliative Care (PC) Within the Treatment of End Stage Liver Disease (ESLD)
Validation of New Prognostic Biomarkers in Patients With Decompensated Cirrhosis
Droxidopa to Increase Mean Arterial Pressure in Decompensated Cirrhosis Patients With Acute Kidney Injury
Effect of Non-Selective Beta-Blockers on Outcomes in Cirrhosis Patients After Hospitalization: A Retrospective Cohort Using Target Trial Design
A Novel COMBinATorial Therapy With Albumin and Enoxaparin in Patients With Decompensated Cirrhosis at High-risk of Poor Outcome (COMBAT Trial).
GCSF Therapy in Decompensated Cirrhosis - A Double Blinded RCT